Get the Stockscreener App
1.68
0.60%
0.01
Pre-market:
1.68
Protalix BioTherapeutics Inc. stock is traded at $1.68, with a volume of 696.40K.
It is up +0.60% in the last 24 hours and down -35.63% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$1.67
Open:
$1.64
24h Volume:
696.40K
Relative Volume:
0.77
Market Cap:
$133.74M
Revenue:
$63.63M
Net Income/Loss:
$10.62M
P/E Ratio:
33.60
EPS:
0.05
Net Cash Flow:
$-8.64M
1W Performance:
+15.07%
1M Performance:
-35.63%
6M Performance:
+3.07%
1Y Performance:
+47.37%
1-Day Range:
$1.62
$1.69
1-Week Range:
$1.47
$1.73
52-Week Range:
$0.8214
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.68 | 116.23M | 63.63M | 10.62M | -8.64M | 0.05 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
What is Zacks Small Cap’s Estimate for PLX Q2 Earnings? - Defense World
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainw - GuruFocus
Protalix BioTherapeutics CFO to Present Latest Biotech Innovations at Exclusive Nasdaq Conference - Stock Titan
PLX: First Quarter Results - MSN
Protalix BioTherapeutics (NYSE:PLX) Lowered to Buy Rating by StockNews.com - Defense World
Protalix BioTherapeutics targets phase 2 launch for PRX-115 in H2 2025 - MSN
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript - Insider Monkey
Protalix: Q1 Earnings Snapshot - New Haven Register
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlig - GuruFocus
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada
Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges - Investing.com
Protalix BioTherapeutics Reports Strong Q1 2025 Growth - TipRanks
Protalix BioTherapeutics (PLX) Sees Revenue Surge Amid Pipeline Advancements - GuruFocus
Small cap wrap: Protalix Biotherapeutics, Delivra Health, HIVE Digital, U.S. Global Investors... - Proactive financial news
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth - Proactive financial news
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results | PLX Stock News - GuruFocus
Protalix BioTherapeutics Inc Reports Q1 2025 Earnings: Revenue at $10.1M, Missing Estimates; EPS at -$0.05, Below Expectations - GuruFocus
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results - PR Newswire
Market Insight: Protalix BioTherapeutics Inc (PLX)’s Notable Drop, Closing at 2.73 - DWinneX
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 - The Malaysian Reserve
Protalix BioTherapeutics to Announce First Quarter 2025 Financia - GuruFocus
Protalix Earnings: Biotech Pioneer to Present Q1 2025 Results and Pipeline Updates May 9 - Stock Titan
Contrasting Genocea Biosciences (NASDAQ:GNCA) & Protalix BioTherapeutics (NYSE:PLX) - Defense World
Can you still get a good price for Protalix BioTherapeutics Inc (PLX) Shares at this point? - uspostnews.com
Fabry Disease Treatment Market Deep Research 2025-2032 | Idorsia Pharmaceuticals Ltd., Protalix BioTherapeutics - openPR.com
HC Wainwright Has Bullish Forecast for PLX Q1 Earnings - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Protalix BioTherapeutics Inc (PLX) - Sete News
Protalix stock soars to 52-week high, hits $3.04 - Investing.com
Protalix stock soars to 52-week high, hits $3.04 By Investing.com - Investing.com India
Monitoring Protalix BioTherapeutics Inc (PLX) after recent insider movements - knoxdaily.com
Protalix BioTherapeutics (PLX) Plans $100 Million Securities Off - GuruFocus
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
PLX’s earnings estimates: Are they on track to meet expectations? - uspostnews.com
Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: A Technical Analysis Perspective - investchronicle.com
Protalix CFO Eyal Rubin to resign in six months By Investing.com - Investing.com India
Protalix BioTherapeutics' CFO Rubin to Leave - MarketWatch
Protalix stock soars to 52-week high, hits $2.76 By Investing.com - Investing.com South Africa
Eyal Rubin Resigns As CFO Of Protalix BiotherapeuticsSEC Filing - marketscreener.com
Protalix CFO Eyal Rubin to resign in six months - Investing.com
Protalix stock soars to 52-week high, hits $2.76 - Investing.com
The growth track for Protalix BioTherapeutics Inc (PLX) has changed recently - Sete News
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):